Study affirms utility of ProFound AI’s Case Scores in improving cancer detection
Company’s Breast AI Suite of deep-learning breast cancer detection, density assessment and risk evaluation tools showcased at largest medical imaging forum in the world
“Leading institutions and experts continue to validate the benefits our Breast AI Suite offers to clinicians and patients alike, establishing our technology as the most widely adopted breast cancer detection solution worldwide,” said
Study affirms utility of ProFound AI’s Case Scores in improving cancer detection
In a digital poster discussion on
ProFound AI increases rate of cancer detection by 27%
In an oral presentation on
“In many European countries, double-reading for mammography is the standard of care, yet this can pose a challenge due to the global shortage of mammography professionals. This can lead to burnout and ultimately, missed cancers,” said Dr. Gräwingholt. “ProFound AI offers a viable and impactful solution. It helps our team find more cancers – and with greater accuracy – demonstrating the real-world value this solution offers as a trustworthy second set of eyes. With this technology, clinicians can feel confident that they are catching cancers earlier, when they may be more easily treated.”
Additional presentations supporting iCAD’s Breast AI Suite to be featured at RSNA
- “Long-term Performance of an Image-based Short-term Risk Model for Breast Cancer” (Oral presentation - Session Number: M6-SSBR04)
Mikael Eriksson , PhD,Department of Medical Epidemiology and Biostatistics ,Karolinska Institute , Solna,Sweden , will present findings from a study that supports iCAD’s first in kind breast cancer risk evaluation tool, ProFound AI® Risk. The study showed ProFound AI Risk has the potential to assess short-term risk for capturing women with estrogen-negative breast cancers in need of supplemental screening and long-term risk for women who could benefit from primary prevention of estrogen-positive breast cancer.
- “Using an Artificial Intelligence System to Implement Limited Double Reading in a Single Reader Environment” (Oral presentation - Session Number: T7-SSBR06)
Robert Nishikawa , PhD, Professor,Department of Radiology ,Imaging Research Laboratory at the University ofPittsburgh Center for Artificial Intelligence Innovation in Medical Imaging, will discuss the feasibility of using ProFound AI to triage selected cases for double reading in a single reader environment. The study showed double reading directed by ProFound AI can efficiently reduce the recall rate by 9%, resulting in only 3% more reads by a second radiologist.
- “Leveraging ProFound AI to Enhance
Patient Care at Solis Mammography” (Oral presentation -AI Showcase Open-Air Theater ) Chirag Parghi , MD, Chief Medical Officer, Solis Mammography, the largest independent provider of mammography and breast health services inthe United States , will share the company’s experience in deploying ProFound AI across its network of facilities.
During the conference, iCAD will also host a series of “Meet the Experts” sessions throughout the week, as well as a “Cocktails and Conversations” event on
About
Headquartered in
Forward-Looking Statements
Certain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about the expansion of access to the Company’s products, improvement of performance, acceleration of adoption, expected benefits of ProFound AI®, the benefits of the Company’s products, and future prospects for the Company’s technology platforms and products. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance, or achievements of the Company to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited, to the Company’s ability to achieve business and strategic objectives, the willingness of patients to undergo mammography screening in light of risks of potential exposure to Covid-19, whether mammography screening will be treated as an essential procedure, whether ProFound AI will improve reading efficiency, improve specificity and sensitivity, reduce false positives and otherwise prove to be more beneficial for patients and clinicians, the impact of supply and manufacturing constraints or difficulties on our ability to fulfill our orders, uncertainty of future sales levels, to defend itself in litigation matters, protection of patents and other proprietary rights, product market acceptance, possible technological obsolescence of products, increased competition, government regulation, changes in Medicare or other reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company; and other risks detailed in the Company’s filings with the
Contacts:
Media inquiries:
+1-201-423-4492
jburns@icadmed.com
Investor Inquiries:
iCAD Investor Relations
ir@icadmed.com
Source:
2022 GlobeNewswire, Inc., source